Can we rely on available models to identify candidates for extended Pelvic Lymph Node Dissection (ePLND) in men staged with PSMA-PET? External validation of the Briganti nomograms and development of a novel tool to identify optimal candidates for ePLND
Multi-parametric MRI-targeted biopsy compared to systematic TRUS biopsy for biopsy-naïve men at risk for prostate cancer: 2 year follow up data and economic analysis
Adverse pathology of prostate cancer after radical prostatectomy. Summary after 7 years and 1500 patients since introduction of mpMRI-guided biopsy in a real world setting
Can intraoperative nerve monitoring improve functional outcomes after unilateral- or non-nerve-sparing robot-assisted radical prostatectomy – a randomized clinical trial
Darolutamide plus androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer by disease volume and risk subgroups in the phase III ARASENS Trial
Rucaparib for metastatic castration-resistant prostate cancer (mCRPC): TRITON3 interim overall survival and efficacy of rucaparib vs docetaxel or second-generation androgen pathway inhibitor therapy